DarioHealth Corp (NASDAQ:DRIO) App Pushes Shares Higher

DarioHealth Corp (NASDAQ:DRIO)

DarioHealth Corp (NASDAQ:DRIO), a developer of App-based diabetes management systems, shares are up over 30% with an hour left in the trading day. Volume for the nano-cap healthcare technology firm are massive. DRIO stock is listed with an average daily trading volume of less than 30,000 shares traded per day. Before the end of trading today already over six million shares have been traded.

NASDAQ:DRIO

DarioHealth Business Model

Israeli-based DarioHealth Corp (NASDAQ:DRIO) develops proprietary technologies using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.

Today DarioHealth Corp (NASDAQ:DRIO) announced that it received the CE Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The news ensures that consumers, beginning in the UK market, will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8.

Erez Raphael, Chairman and CEO of DarioHealth Corp (NASDAQ:DRIO), commented, “We’ve been working tirelessly to bring forth a solution that would meet the rigorous standards required to achieve the CE Mark. We are proud that our organization worked with agility to ensure connectivity to the latest Apple devices. This significant milestone will allow us to open to a whole new market segment and reengage with former-Dario users who now have the newest Apple devices.”

DRIO Stock

DRIO stock tried to break through the $3 level back in May but without success. The shares then slid and traded in a $1.80-$2.00 range for the last several weeks. Shares are still down over 40% YTD and well below their 52-week high of $4.70. DRIO stock has a $4.25 price target by the lone analyst that covers the shares and assigns DRIO a rating of “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Social Reality Inc. (NASDAQ:SRAX) Affirms Commitment

Social Reality Inc. (NASDAQ:SRAX)

Social Reality Inc. (NASDAQ:SRAX) shares nearly doubled in value after the advertising technology company announced it had engaged the services of financial advisors to explore strategic alternatives for the SRAXmd business. The stock was up by 70.7% in Tuesday’s trading session to end the day at $4.90 a share.

SRAX Stock Performance

Tuesday’s rally helped affirm a bullish run that began late last month, which has seen the stock bounce from multi-year lows, near the $1 a share mark. While the stock is still down by more than 10% for the year, it continues to trade in an uptrend after erasing some losses.

Renewed investors interest in the advertising technology company comes on growing confidence surrounding the company’s commitment to growing shareholder value. One of the strategic alternatives that Social Reality Inc. (NASDAQ:SRAX) is exploring for the SRAXmd business is strategic acquisitions that have the potential to support the core business.

Social Reality is also considering spinning off some of its business units into its own public company in pursuit of shareholder value. SRAX works with healthcare and pharmaceutical companies to engage healthcare professional’s patient and caregivers through mobile and digital advertising. The firm boasts of a patent-pending platform that is designed to allow for event-triggered response for targeting HCP facilities.

“The ability to positively impact patient outcomes through real-time mobile targeting to professionals is the future of Non-Personal Promotion. We have delivered 100% year-over-year revenue growth for SRAXmd since the rollout of MD products in 2014. Non-Personal Promotion continues to evolve at a more rapid rate than traditional methodologies,” said Chief Innovations Officer Erin DeRuggiero.

Demand Side Platform Acquisition

A move to pursue strategic alternatives for the SRAXmd business follows the acquisition of Demand Side Platform, a technology firm focused on marketing experimentation and optimization of brands. The privately-held firm has helped develop a unique DSP with Real-Time Bidding and targeting capabilities that Social Reality Inc. (NASDAQ:SRAX) expects to bond well with SRAX platform.

“Not only does the technology acquired complement our DSP, but it will also be powerful and valuable to the buy-side of our business serving brands and agencies,” said CEO, Christopher Million.

Separately, Social Reality Inc. (NASDAQ:SRAX) has appointed Veteran Matt Weiss to its Board of Directors. He joins the company having worked for some of the largest advertising agencies in the world such as Havas Worldwide and McCann World group.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRAX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

MagneGas Corporation (NASDAQ:MNGA) Receives $1.58 Million Order

MagneGas Corporation (NASDAQ:MNGA)

MagneGas Corporation (NASDAQ:MNGA) shares fell 6.10% after the clean technology company announced the sale of a gasification unit for $1.58 million. The order builds on a previously announced consulting agreement in Europe where the company is aggressively pursuing sales opportunities.

MagneGas Corporation (NASDAQ:MNGA)

Europe Sales Push

Investor’s reaction, however, has not been good even as the company moves to pursue new sales opportunities beyond Germany. The stock continues to languish near all-time lows after remaining under pressure for the better part of the year. MagneGas Corporation is down by more than 80% for the year.

According to the Chief Executive Officer, Ermanno Santilli, the sale is a milestone achievement as it helps build a pipeline that the company will be able to leverage in the coming months. The unit will be placed in the Nordics region for the production of MagneGas2 from Butanol. It may also be placed in continental Europe at large steel mill.

The sale builds on a$1.9 million deal that MagneGas Corporation (NASDAQ:MNGA) inked early in the month for a gasification unit for the production of MagneGas2 in European markets.

“We were impressed by the quality of the opportunity pipeline that our distributor in Europe has developed in a relatively short period of time and this latest opportunity demonstrates continued success in penetrating a customer base which is ready for a replacement product to legacy acetylene,” commented MagneGas CFO Scott Mahoney.

MagneGas Consulting Contract

In addition, MagneGas Corporation has been contracted by a European partner to provide consulting services focused on identifying and validating the application of their proprietary technology in Europe. The value of the contract is $500,000 and could increase to $1 million – depending on the scope.

Under terms of the deal, the clean technology company is to gain access to an approved range of testing facilities that are approved for waste streams. MagneGas Corporation (NASDAQ:MNGA) is also tasked with the responsibility of determining the economic value and technical feasibility of new gasification and sterilization solutions in Europe. Mr. Mahoney expects the contract to further accelerate the company’s commercialization efforts in Europe.

“There is significant pent-up demand in Europe, due to the regulatory environment and other factors, which represents an immediate and sizable market opportunity for MagneGas,” said Mr. Mahoney.

Separately, MagneGas Corporation (NASDAQ:MNGA) has signed a Letter of Intent for the acquisition of an independent industrial gas and welding supply business, expected to generate over $1.6 million in annual revenues.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNGA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Recon Technology, Ltd. (NASDAQ:RCON) Pops!

Recon Technology, Ltd. (NASDAQ:RCON)

Recon Technology, Ltd. (NASDAQ:RCON)

By 3 PM EST Recon Technology, Ltd. (NASDAQ:RCON) shares had traded hands over 20 million times. Its 30-day, daily trading average is 20,140 which makes today’s volume figure over 1,200 times the average. At the time of this writing RCON shares are trading around the $2.28 level after closing Friday at $1.02. The catalyst for the 120%+ move hat it has signed a three-year strategic cooperation agreement (“Agreement”) with Beijing OriginWater Purification Engineering Technology Co., Ltd (“BOW Engineering”). According to terms of the agreement, Recon Technology and BOW Engineering will collaborate and promote advanced sewage treatment technology in the Chinese oilfield markets. Together they will also supply solutions and services of superior quality and effectiveness to tackle industrial water pollution.

Mr. Shenping Yin, CEO of Recon Technology stated in the press release “Chinese government as well as large oil companies are dedicated to protecting the environmental during oil production and seeking more efficient techniques and equipment to realize cost-saving and meet increasingly stringent environmental protection requirement… With its abundant market experience, deep insights and visions in oilfield markets, and support of BOW’s team of specialists, we believe Recon will maintain research and technological advantages and deliver better performance.”

Beijing OriginWater Technology Co. Ltd. addresses China’s three main water challenges: water pollution, water shortage and confidence in the drinking water supply. BOW is one of the world largest water-membrane technology enterprises and is also a leading developer of environmental protection enterprises.

Before today’s trading, RCON stock’s 52-week high was $1.93, reached late last year. Its 52-week low was $0.64 which was reached last month. 15% of the share’s float is held by short-sellers – a number that will likely decline given the positive news. Insiders own 53% of the shares and institutions own less than 1%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RCON and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Capstone Turbine Corporation (NASDAQ:CPST) Cost Cutting Drive

Capstone Turbine Corporation (NASDAQ:CPST)

Capstone Turbine Corporation (NASDAQ:CPST) shares fell 7.76% after the leading manufacturer of microturbine energy systems announced a reduction in its quarterly operating-expense target. The company has lowered, following the restructuring of engineering assets and other cost reduction activities, its target from $5.5 million per quarter to $5 million.

CPST Stock Performance

Shares of Capstone Turbine had initially recorded a new 52-week high of $1.38 a share after Oppenheimer analysts upgraded the stock to an ‘outperform’. However, the stock came under pressure in Friday’s trading session as it dropped to end the week at $1.70 a share.

Capstone Turbine Corporation (NASDAQ:CPST) is currently trading in an uptrend despite Friday’s sell-off. A price target of $2 by Oppenheimer analysts appears to have strengthened sentiments on the stock. The analysts see potential upside in the stock price, given that the company is set to move its manufacturing operations to a more affordable space as it also continues to aggressively manage its supply chain.

 

Capstone Turbine Corporation (NASDAQ:CPST) has also announced that it is completing the previously announced $5.2 million retrofit program. The program seeks to upgrade non-signature series C100 and C200 microturbine to provide improved performance and reliability.

Capstone Forecast

According to Capstone Turbine Corporation (NASDAQ:CPST), improved reliability of the microturbine coupled with high performing Signature series microturbine could drive higher gross margins in the accessories, parts, and service divisions.

“We need to drive Capstone to profitability as quickly as possible in order to fuel Capstone’s launch to the next level of product development and market penetration. Our aftermarket service business growth is a critical element of our multi-point strategic plan to quickly achieve Adjusted EBITDA breakeven,” said CEO Darren Jamison.

Capstone Turbine Corporation (NASDAQ:CPST) is targeting revenues of up to $10 million, on gross margins of 50%, for its accessories, parts, and service business. The company has moved from a high-cost, three department research and development effort to a single consolidated department in pursuit of lower costs and improved efficiency on product optimization. Operating expenses as a result dropped 42% from $10.5 million as of Q1 2016 to $6.1 million in Q3 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CPST Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) Falls After Pricing

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) shares fell 25.3% after the biopharmaceutical company announced the signing of definitive agreements with certain institutional and accredited investors. Pursuant to the agreement, the company will sell an aggregate of 7.95 million shares of its common stock and warrants for the purchase of additional shares.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Public Offering Reaction

Investors reacted to the news by sending the stock lower as the issuance of shares will result in further dilution of the stock. Last week’s sell-off is already threatening to reverse a bullish run that had pushed the stock to a 52-week high of $4.84 a share. Over the past few days, the stock has shed more than 40% in market value. However, it is still up by more than 100% for the year.

The biopharmaceutical company is expecting approximately $23.8 million from the registered direct offering. Net proceeds from the offering are to be used to support business development projects.

In addition, CASI Pharmaceuticals Inc. (NASDAQ:CASI) Chairman Dr. Wei-Wu He has echoed his support for China’s FDA push to accept data from clinical trials outside China. According to the executive, the move will accelerate approval of imported drugs.

“We believe this could potentially accelerate our pipeline of U.S. approved drugs that are currently under China FDA review, namely EVOMELA®, which has been granted priority review; and MARQIBO® and ZEVALIN®. We look forward to accelerating these medicines to the second largest pharmaceutical market, and will continue to add on to our pipeline,” said Mr. He.

CFDA Import Drug Accelerated Approval

China’s FDA has already granted a priority review for EVOMELA, for the treatment of multiple myeloma, which is classified as a rare disease in the country. The agency is also reviewing an application for approval of MARQIBO for the treatment of adult patients with Philadelphia chromosome negative lymphoblastic leukemia. A review of the drug is set to be complete in the next four to six weeks.

The CFDA is also reviewing, CASI Pharmaceuticals Inc. (NASDAQ:CASI) import drug clinical trial application (CTA) for ZEVALIN. The intravenous injection is indicated for the reduction of the number of B-cells in the blood and for the treatment of non-Hodgkin’s lymphoma (NHL).

“[..] it also is a positive signal from the CFDA to accelerate the import drug registration process for U.S. FDA approved drugs in order to address the significant unmet medical needs of the Chinese population in an accelerated time frame,” said CEO, Ken Ren.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CASI Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Traders Cautious on Jump in Leading Brands, Inc (USA) (NASDAQ:LBIX) Stock

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Nano-cap Leading Brands, Inc (USA) (NASDAQ:LBIX) stocked rocketed over 68% Friday to end the day at $2.27 on volume over 128 times its 30-day, daily average.

Leading Brands, Inc (USA) (NASDAQ:LBIX)

About Leading Brands Inc.

Nano-cap Leading Brands, Inc (USA) (NASDAQ:LBIX) is headquartered in Vancouver, BC, Canada. It develops, markets, and distributes beverages in Canada, the western United States, and Asia. The company’s core product lines include premium spring waters and fruit juices. The company was formerly known as Brio Industries Inc. and changed its name to Leading Brands, Inc. in October 1999.

Some nano-cap observers believe the dramatic increase of Leading Brands, Inc (USA) (NASDAQ:LBIX) stock last week could be due to speculation that traders may be betting on a play in the near future by a braoder market than usual based on the recent moves by former nano-cap Helios and Matheson Analytics Inc (NASDAQ:HMNY). HMNY shares are up over 675% in the past month.

However, it should be noted that while LBIX shares have increased 134% over the past month, the beverage company has not released any news that would point to a dramatic increase in revenues or earnings as Helios and Matheson Analytics did.

LBIX Stock

In 2015, Leading Brands, Inc (USA) (NASDAQ:LBIX) posted sales of $400,000 and that sales figure improved to $1 million for 2016. Also to the benefit of LBIX shareholders is the fact that, according to reports, the number of outstanding shares has declined each year since 2013. However LBIX shares have posted per share losses each of the last three years, In 2015 investors lost (-$1.05) per share, (-$1.09) in 2015, and (-$0.88) for 2016.

Until last week, shares of Leading Brands, Inc (USA) (NASDAQ:LBIX) had been sliding since May when they last hit $2.27. The price action on Friday saw LBIX shares hit an inter-day high of $3.75 which is considerably over their 52-week high of $2.92.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LBIX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Big Move for Clean Diesel Technologies, Inc. (NASDAQ:CDTI)

Clean Diesel Technologies, Inc. (NASDAQ:CDTI)

Clean Diesel Technologies, Inc. (NASDAQ:CDTI) stock rocketed up over 28% in Friday’s trading on the back of over 5 million shares traded – over 35 times the stock’s 30-day, daily average. The Thursday close of $1.65 was just $0.13 above the 52-week low of $1.52 which was hit in August. However, CDTI shares are still over 43% below their 52-week high of $3.72 that was hit last May.

Clean Diesel Technologies, Inc. (NASDAQ:CDTI)

Clean Technologies Business Model

Clean Diesel Technologies, Inc. (NASDAQ:CDTI) is a global manufacturer and distributor of heavy duty diesel and light duty vehicle emissions control systems and products to major automakers and retrofitters. Accordingly, their business is largely moved by legislation addressing global emission standards in response to government concerns over the effects of fossil fuel usage.

The company has two revenue producing channels. Their Heavy Duty Diesel Systems Division specializes in the design and manufacture of verified exhaust emission control solutions. Their Catalyst Division produces catalyst formulations for gasoline, diesel and natural gas-induced emissions.

CDTI Stock

Clean Diesel Technologies, Inc. (NASDAQ:CDTI) has a market capitalization under $50 million and CDTI is considered a micro-cap stock. However they have considerable sales revenues for a company their size although the figures have been declining. In 2012, Clean Diesel Technologies, Inc. (NASDAQ:CDTI) reported sales of $60.5 million. That number has declined year-on-year and for 2016 the reported figure was just $36.8 million. Earnings have not been pleasant for the investors either. In 2012 the loss was (-$6.71) per share. That figure shrank each of the successive three years and in 2015 the per share loss was only (-$2.67). Unfortunately, the loss expanded in 2016 to (-$3.84). Dilution has also weighed on CDTI stockholders. The number of outstanding shares has increased from 1.45 million in 2012 to 6.11 million in 2016.

The consensus target price for CDTI stock is $3.00 – around 48% higher than where the shares are currently valued.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CDTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Real Goods Solar, Inc. (NASDAQ:RGSE) Awarded New Haven Contract

Real Goods Solar, Inc. (NASDAQ:RGSE)

Real Goods Solar, Inc. (NASDAQ:RGSE) shares gained 23.5% after Solarize New Haven selected the solar company to provide solar electricity to homes and business in New Haven, Connecticut. The campaign is to begin on October 18, 2017, and set to run through March 7, 2018. Smart Power, the nation’s leading nonprofit marketing firm, has been selected to market the campaign as it is experienced with community-based energy programs.

“We are thrilled to be joining forces with Solarize Connecticut once again for what we believe will be another successful Solarize program,” said Tom Champlin, Director of sales at RGS Energy. “We will provide our exceptional service to New Haven, supported by our 31 local Connecticut employees, based out of our 10,000 square foot, centrally located, warehouse in Bloomfield.”

Overall, Real Goods Solar, Inc. (NASDAQ:RGSE) shares have suffered in the market. RGSE stock is down by more than 70% for the year. However, the stock has shown some signs of recovery as investors react to the signing of an exclusive domestic and international license agreement with Dow Chemical Co (NYSE:DOW).

Real Goods Solar, Inc. (NASDAQ:RGSE)

RGS Energy – DOW Agreement

Under the terms of the agreement, RGS is to lead commercial activities for the POWERHOUSE solar shingles stem, developed by DOW.  The company is also to handle supply chain management, marketing, sales installation, and warranty.

The POWERHOUSE solar shingles are designed to be aesthetically more pleasing than a traditional solar array.  RGS plans to expand the network of authorized local roofers to achieve lower cost of customer acquisition as it moves to market the shingle.

The company also plans to engage in direct sales with new home builders in a bid to attract more orders. RGS will also expand its call center and digital marketing program to aggressively market the product.

“We believe that RGS is well positioned to optimize the market potential for POWERHOUSE™ 3.0 solar shingles system. The design of POWERHOUSE™ 3.0 solar shingles addresses the critical requirements of customers and installers and achieves a price point that will be very competitive,” said Kirk Thompson, Business Director of Dow Solar.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RGSE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.